Journal
MOVEMENT DISORDERS
Volume 28, Issue 7, Pages 1001-1012Publisher
WILEY
DOI: 10.1002/mds.25552
Keywords
dystonia; botulinum toxin; baclofen; trihexyphenidyl; tetrabenazine
Categories
Funding
- Allergan, Inc.
- Ipsen Limited
- Merz Pharmaceuticals
Ask authors/readers for more resources
Medications such as anticholinergic drugs, dopamine modulators, baclofen, muscle relaxants, and other pharmacologic agents have been used for a long time to treat dystonia, but the introduction of botulinum toxin and deep brain stimulation clearly revolutionized the symptomatic treatment of this neurological movement disorder. Therapy of dystonia can be divided into the following categories: (1) physical, supportive, and ancillary therapy; (2) pharmacologic treatment; (3) chemodenervation with botulinum toxin; and (4) peripheral and central surgery (deep brain stimulation). Except in some cases of secondary dystonia, pathogenesis-targeted or disease-modifying therapy is currently not available. This review focuses on evidence-based medical treatment of dystonia, highlighting recent advances, with emphasis on individualized approach. (C) 2013 Movement Disorder Society
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available